Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: A meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 7, 2015, Pages 10235-10247

  Luo, Yihuan ^a   Ren, Fanghui ^a   Liu, Yongru ^a   Shi, Zhenhong ^a   Tan, Zhong ^a   Xiong, Huojie ^a   Dang, Yiwu ^a   Chen, Gang ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathological features; Hepatocellular carcinoma (HCC); Ki 67; Meta analysis; Prognostic value

Indexed keywords

KI 67 ANTIGEN;

CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CLINICAL ASSESSMENT; DISEASE FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; REVIEW; TUMOR INVASION; TUMOR VOLUME;

EID: 84940644730     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Cai ZQ, Si SB, Chen C, Zhao Y, Ma YY, Wang L, Geng ZM. Analysis of prognostic factors for survival after hepatectomy for hepatocellular carcinoma based on a bayesian network. PLoS One 2015; 10: e0120805.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
3. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607-15.
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
5. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008; 48: 2047-63.
6. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer I, Kloth S, Brandt E, Flad HD. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991; 138: 867-73.
7. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984; 133: 1710-5.
8. Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res 2006; 12: 143-7.
9. Moul JW. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 1999; 35: 399-407.
10. Patil DT, Chou PM. Sialoblastoma: utility of Ki-67 and p53 as a prognostic tool and review of literature. Pediatr Dev Pathol 2010; 13: 32-8.
11. Jamali M, Chetty R. Predicting prognosis in gastroentero-pancreatic neuroendocrine tumors: an overview and the value of Ki-67 im munostaining. Endocr Pathol 2008; 19: 282-8.
12. Jakobsen JN, Sorensen JB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer 2013; 79: 1-7.
13. Pathmanathan N, Balleine RL. Ki67 and proliferation in breast cancer. J Clin Pathol 2013; 66: 512-6.
14. Chiloiro S, Bianchi A, Doglietto F, de Waure C, Giampietro A, Fusco A, Iacovazzo D, Tartaglione L, Di Nardo F, Signorelli F, Lauriola L, Anile C, Rindi G, Maira G, Pontecorvi A, De Marinis L. Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary 2014; 17: 267-76.
15. Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, Lafitte JJ, Sculier JP. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004; 91: 2018-25.
16. de Azambuja E, Cardoso F, de Castro G Jr, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007; 96: 1504-13.
17. He X, Chen Z, Fu T, Jin X, Yu T, Liang Y, Zhao X, Huang L. Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. BMC Cancer 2014; 14: 153.
18. Chen WJ, He DS, Tang RX, Ren FH, Chen G. Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis. Asian Pac J Cancer Prev 2015; 16: 411-20.
19. Pan D, Wei K, Ling Y, Su S, Zhu M, Chen G. The Prognostic Role of Ki-67/MIB-1 in Cervical Cancer: A Systematic Review with Meta-Analysis. Med Sci Monit 2015; 21: 882-9.
20. Stroescu C, Dragnea A, Ivanov B, Pechianu C, Herlea V, Sgarbura O, Popescu A, Popescu I. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma. J Gastrointestin Liver Dis 2008; 17: 411-7.
21. Sofocleous CT, Garg S, Petrovic LM, Gonen M, Petre EN, Klimstra DS, Solomon SB, Brown KT, Brody LA, Covey AM, Dematteo RP, Schwartz L, Kemeny NE. Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies. Ann Surg Oncol 2012; 19: 4262-9.
22. Schmilovitz-Weiss H, Tobar A, Halpern M, Levy I, Shabtai E, Ben-Ari Z. Tissue expression of squamous cellular carcinoma antigen and Ki67 in hepatocellular carcinoma-correlation with prognosis: a historical prospective study. Diagno Pathol 2011; 6: 121.
23. Morinaga S, Ishiwa N, Noguchi Y, Yamamoto Y, Rino Y, Imada T, Takanashi Y, Akaike M, Sugimasa Y, Takemiya S. Growth index, assessed with Ki-67 and ssDNA labeling; a significant prognosticator for patients undergoing curative resection for hepatocellular carcinoma. J Surg Oncol 2005; 92: 331-6.
24. Ktas S, Karakayali H, Moray G, Ozdemir H, Haberal M. Effects of risk factors and Ki-67 on rates of recurrence on patients who have undergone liver transplant for hepatocellular carcinoma. Transplant Proc 2011; 43: 3807-12.
25. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-34.
26. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med 1997; 127: 820-6.
27. Murakami K, Kasajima A, Kawagishi N, Ohuchi N, Sasano H. Microvessel density in hepatocellular carcinoma: Prognostic significance and review of the previous published work. Hepatol Res 2015; [Epub ahead of print].
28. Jang KY, Noh SJ, Lehwald N, Tao GZ, Bellovin DI, Park HS, Moon WS, Felsher DW, Sylvester KG. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One 2012; 7: e45119.
29. Srivastava S, Wong KF, Ong CW, Huak CY, Yeoh KG, Teh M, Luk JM, Salto-Tellez M. A morpho-molecular prognostic model for hepatocellular carcinoma. Br J Cancer 2012; 107: 334-9.
30. Geng M, Cao YC, Chen YJ, Jiang H, Bi LQ, Liu XH. Loss of Wnt5a and Ror2 protein in hepatocellular carcinoma associated with poor prognosis. World J Gastroenterol 2012; 18: 1328-38.
31. Chen HW, Huang XD, Li HC, He S, Ni RZ, Chen CH, Peng C, Wu G, Wang GH, Wang YY, Zhao YH, Zhang YX, Shen AG, Wang HM. Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients' prognosis and tumor cell proliferation. Mol Carcinog 2013; 52: 647-59.
32. Jiang D, Hu B, Wei L, Xiong Y, Wang G, Ni T, Zong C, Ni R, Lu C. High expression of vacuolar protein sorting 4B (VPS4B) is associated with accelerated cell proliferation and poor prognosis in human hepatocellular carcinoma. Pathol Res Prac 2015; 211: 240-7.
33. Huang X, Cong X, Yang D, Ji L, Liu Y, Cui X, Cai J, He S, Zhu C, Ni R, Zhang Y. Identification of Gem as a new candidate prognostic marker in hepatocellular carcinoma. Pathol Res Prac 2014; 210: 719-25.
34. Hu B, Xiong Y, Ni R, Wei L, Jiang D, Wang G, Wu D, Xu T, Zhao F, Zhu M, Wan C. The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma. Mol Cell Biochem 2014; 396: 175-85.
35. Huang X, Wang X, Cheng C, Cai J, He S, Wang H, Liu F, Zhu C, Ding Z, Huang X, Zhang T, Zhang Y. Chaperonin containing TCP1, subunit 8 (CCT8) is upregulated in hepatocellular carcinoma and promotes HCC proliferation. APMIS 2014; 122: 1070-9.
36. Chen H, Miao J, Li H, Wang C, Li J, Zhu Y, Wang J, Wu X, Qiao H. Expression and prognostic significance of p21-activated kinase 6 in hepatocellular carcinoma. J Surg Res 2014; 189: 81-8.
37. Huang X, Liu F, Zhu C, Cai J, Wang H, Wang X, He S, Liu C, Yao L, Ding Z, Zhang Y, Zhang T. Suppression of KIF3B expression inhibits human hepatocellular carcinoma proliferation. Dig Dis Sci 2014; 59: 795-806.
38. Lu C, Liu G, Cui X, Zhang J, Wei L, Wang Y, Yang X, Liu Y, Cong X, Lv L, Ni R, Huang X. Expression of SGTA correlates with prognosis and tumor cell proliferation in human hepatocellular carcinoma. Pathol Oncol Res 2014; 20: 51-60.
39. Liu G, Huang X, Cui X, Zhang J, Wei L, Ni R, Lu C. High SKIP expression is correlated with poor prognosis and cell proliferation of hepatocellular carcinoma. Med Oncol 2013; 30: 537.
40. Lu C, Zhang J, He S, Wan C, Shan A, Wang Y, Yu L, Liu G, Chen K, Shi J, Zhang Y, Ni R. Increased alpha-tubulin1b expression indicates poor prognosis and resistance to chemotherapy in hepatocellular carcinoma. Dig Dis Sci 2013; 58: 2713-20.
41. Chen LT, Lin LJ, Zheng LL. The correlation between insulin-like growth factor II mRNA binding protein 3 expression in hepatocellular carcinoma and prognosis. Hepatogastroenterology 2013; 60: 553-6.
42. Cao X, Xia Y, Yang J, Jiang J, Chen L, Ni R, Li L, Gu Z. Clinical and biological significance of never in mitosis gene A-related kinase 6 (NEK6) expression in hepatic cell cancer. Pathol Oncol Res 2012; 18: 201-7.
43. He S, Lu M, Xue W, Wang Y, Zhao Y, Gao S, Ke Q, Liu Y, Li P, Cui X, Cheng C, Shen A. Phosphorylated p27Kip1 on Thr157 is an important prognosis in human hepatocellular carcinoma in vivo and in vitro. Med Oncol 2011; 28: 94-104.
44. Ke Q, Ji J, Cheng C, Zhang Y, Lu M, Wang Y, Zhang L, Li P, Cui X, Chen L, He S, Shen A. Expression and prognostic role of Spy1 as a novel cell cycle protein in hepatocellular carcinoma. Exp Mol Pathol 2009; 87: 167-72.
45. Yang SF, Wang SN, Wu CF, Yeh YT, Chai CY, Chunag SC, Sheen MC, Lee KT. Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol 2007; 60: 642-8.
46. Wang SN, Chuang SC, Yeh YT, Yang SF, Chai CY, Chen WT, Kuo KK, Chen JS, Lee KT. Potential prognostic value of leptin receptor in hepatocellular carcinoma. J Clin Pathol 2006; 59: 1267-71.
47. Schmitt-Graeff A, Ertelt-Heitzmann V, Allgaier HP, Olschewski M, Nitschke R, Haxelmans S, Koelble K, Behrens J, Blum HE. Coordinated expression of cyclin D1 and LEF-1/TCF transcription factor is restricted to a subset of hepatocellular carcinoma. Liver Int 2005; 25: 839-47.
48. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005; 103: 307-12.
49. Watanabe J, Kushihata F, Honda K, Sugita A, Tateishi N, Mominoki K, Matsuda S, Kobayashi N. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 2004; 135: 604-12.
50. Aoki T, Inoue S, Imamura H, Fukushima J, Takahashi S, Urano T, Hasegawa K, Ogushi T, Ouchi Y, Makuuchi M. EBAG9/RCAS1 expression in hepatocellular carcinoma. Eur J Cancer 2003; 39: 1552-61.
51. Srivastava S, Thakkar B, Yeoh KG, Ho KY, Teh M, Soong R, Salto-Tellez M. Expression of proteins associated with hypoxia and Wnt pathway activation is of prognostic significance in hepatocellular carcinoma. Virchows Archiv 2015; 466: 541-8.
52. Cui J, Dong BW, Liang P, Yu XL, Yu DJ. Construction and clinical significance of a predictive system for prognosis of hepatocellular carcinoma. World J Gastroenterol 2005; 11: 3027-33.
53. Matsuda Y, Ichida T, Genda T, Yamagiwa S, Aoyagi Y, Asakura H. Loss of p16 contributes to p27 sequestration by cyclin D(1)-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res 2003; 9: 3389-96.
54. Morinaga S, Nakamura Y, Ishiwa N, Yoshikawa T, Noguchi Y, Yamamoto Y, Rino Y, Imada T, Takanashi Y, Akaike M, Sugimasa Y, Takemiya S. Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. Oncol Rep 2004; 12: 1189-94.
55. Fiorentino M, Altimari A, Ravaioli M, Gruppioni E, Gabusi E, Corti B, Vivarelli M, Bringuier PP, Scoazec JY, Grigioni WF, D'Errico-Grigioni A. Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation. Clin Cancer Res 2004; 10: 1789-95.
56. Kitamura K, Hatano E, Higashi T, Narita M, Seo S, Nakamoto Y, Yamanaka K, Nagata H, Taura K, Yasuchika K, Nitta T, Uemoto S. Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol 2011; 55: 846-57.
57. Mitsuhashi N, Kobayashi S, Doki T, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, Nozawa S, Furukawa K, Takeuchi D, Suda K, Miura S, Miyazaki M. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23: e189-97.
58. Guzman G, Alagiozian-Angelova V, Layden-Almer JE, Layden TJ, Testa G, Benedetti E, Kajdacsy-Balla A, Cotler SJ. p53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients. Mod Pathol 2005; 18: 1498-503.
59. Ito Y, Matsuura N, Sakon M, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Monden M. Both cell proliferation and apoptosis significantly predict shortened disease-free survival in hepatocellular carcinoma. Br J Cancer 1999; 81: 747-51.
60. Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N. Expression and prognostic role of cyclin-dependent kinase 1 (cdc2) in hepatocellular carcinoma. Oncology 2000; 59: 68-74.
61. King KL, Hwang JJ, Chau GY, Tsay SH, Chi CW, Lee TG, Wu LH, Wu CW, Lui WY. Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 1998; 13: 273-9.
62. Ng IO, Na J, Lai EC, Fan ST, Ng M. Ki-67 antigen expression in hepatocellular carcinoma using monoclonal antibody MIB1. A comparison with proliferating cell nuclear antigen. Am J Clin Pathol 1995; 104: 313-8.
63. Nolte M, Werner M, Nasarek A, Bektas H, von Wasielewski R, Klempnauer J, Georgii A. Expression of proliferation associated antigens and detection of numerical chromosome aberrations in primary human liver tumours: relevance to tumour characteristics and prognosis. J Clin Pathol 1998; 51: 47-51.
64. Zhang L, Li SM, Zhang HJ, Wu YJ. Expression of CD34, 8-OHdG and Ki67 in patients with HBV-HCC and their significances to prognosis of HCC. Cancer Research on Prevention and Treament 2012; 39: 547-50.
65. Chen XG, Wu LM, Xu XB, Feng XW, Xie HY, Zhang M, Shen Y, Wang WL, Liang YB, Zheng SS. Prognostic role of biomarkers applied to hepatocellular carcinom a patients treated with orthotopic liver transplantation. Chinese Journal of Pathophysiology 2008; 24: 311-4.
66. Guo J. Expression and significance of COX-2, Ki-67, survivin in hepatocellular carcinoma. Tianjin medical university (master thesis), 2006.
67. Han SH, Huang JF. Significance of Ki-67 antigen expression in hepatocellular carcinoma. Chinese Journal of General Surgery 2000; 9: 42-5.
68. He P, Zhang YR, Xu XD, Che LH, Wu HX, Xue L. Analysis of the related factors which affect tumor biological behavior and prognosis in hepatocellular carcinoma. Chinese Journal of Clinical and Experimental Pathology 2006; 22: 61-4.
69. Pang XF, Wang ZS, Sun SG, Wu LQ. The significance of p53, Ki-67 expression in hepatocellular carcinoma tissue. Shandong Medical Journal 2011; 51: 34-5.
70. Pang XF, Wang ZS, Wu LQ. Significance of Ki-67 expression in the prognosis of patients with short-term recurrence of hepatocellular carcinoma after radical resection hepatectomy. Chinese Journal of hepatic surgery (Electronic Edition) 2012; 1: 123-8.
71. Sun SG. The expression of p53, E-cadherin and ki-67 in hepatocellular carcinoma tissues and prognosis of the patients after hepatectomy. Qingdao university (master thesis), 2010.
72. Wang NF, Zhao RY, Feng XD, Lv PP, Zhang L. The clinical significance of Ki-67 expression in hepatocellular carcinoma. Journal of Dalian University 2003; 24: 71-3+9.
73. WAF1, p53 and Ki-67 in hepatocellular carcinoma: a pathological study. Medical Journal of Chinese People's Liberation Army 2014; 39: 20-4.
74. Zhang YR, Xue L, He P, Che LH. Analysis of the related factors which affect tumor biological behavior and prognosis in hepatocellular carcinoma. Journal of Sun Yat-sen University (Medical Sciences) 2007; 28: 19-21.
75. Zheng SS, Shen HJ, Chen XH, Ren ZG, Zhang FH, Yin X, Du M, Wang JX, Qiu SJ. Correlation between Ki-67 and early recurrence of hepatocellular carcinoma after radical resection. Chinese Journal of Digestion 2014; 34: 316-20.
76. Chen HW, Wang CH, Li JL, Zhu Y, Wang JX, Wu X. The significance of p21-activated protein 6 expression in hepatocellular carcinoma kinase. Chinese Journal of Clinical and Experimental Pathology 2014; 30: 313-7.
77. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
78. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-42.
79. Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Gene : TIG 2004; 20: 439-44.